Diabetes care credit system: A model for comprehensive and optimal diabetes care

Endocrine Practice

Volumn 10, Issue 3, 2004, Pages 187-194

  Abbasi, Ali A ^a   Grunberger, George ^a   Parikh, Swapna ^a   Nicola, Monica ^a   Gherlan, Claudiu ^a   Turan, Aydin ^a   Vitale, Massimiliano ^a   Dave, Hetal ^a   Amin, Mohammad ^a   Johnson, Debbie ^a  

^a Grunberger Diabetes Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; DIABETES MELLITUS; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT PARTICIPATION; PRACTICE GUIDELINE; THEORETICAL MODEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DELIVERY OF HEALTH CARE; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT CARE; PATIENT PARTICIPATION; PRACTICE GUIDELINES; QUALITY OF HEALTH CARE;

EID: 16644400096     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.10.3.187     Document Type: Article

References (47)

1. Janes GR. Ambulatory medical care for diabetes. In: Harris MI, Bennett PH, Boyko EJ, et al (National Diabetes Data Group), eds. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health, 1995: 541-552.
2. Chin MH, Cook S, Jin L, et al. Barriers to providing diabetes care in community health centers. Diabetes Care. 2001;24:268-274.
3. Clark CM Jr, Snyder JW, Meek RL, Stutz LM, Parkin CG. A systematic approach to risk stratification and intervention within a managed care environment improves diabetes outcomes and patient satisfaction. Diabetes Care. 2001;24:1079-1086.
4. O'Connor PJ. Organizing diabetes care: identify, monitor, prioritize, intensify. Diabetes Care. 2001;24:1515-1516.
5. Dinneen SF. Towards an optimal model for community-based diabetes care: design and baseline data from the Mayo Health System Diabetes Translation Project. J Eval Clin Pract. 2000;6:421-430.
6. Chin MH, Auerbach SB, Cook S. Quality of diabetes care in community health centers. Am J Public Health. 2000;90:431-434.
7. Bell RA, Camacho F, Goonan K, et al. Quality of diabetes care among low-income patients in North Carolina. Am J Prev Med. 2001;21:124-131.
8. Kirkman MS, Williams SR, Caffrey HH, Marrero DG. Impact of a program to improve adherence to diabetes guidelines by primary care physicians. Diabetes Care. 2002;25:1946-1951.
9. Larme AC, Pugh JA. Evidence-based guidelines meet the real world: the case of diabetes care. Diabetes Care. 2001;24:1728-1733.
10. Peterson KA, Vinicor F. Strategies to improve diabetes care delivery. J Fam Pract. 1998;47(5 Suppl):S55-S62.
11. Nyman MA, Murphy ME, Schryver PG, Naessens JM, Smith SA. Improving performance in diabetes care: a multicomponent intervention. Eff Clin Pract. 2000;3:205-212.
12. Fleming BB, Greenfield S, Engelgau MM, Pogach LM, Clauser SB, Parrott MA. The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic [erratum in Diabetes Care. 2002;25:249]. Diabetes Care. 2001;24:1815-1820.
13. Renders CM, Valk GD, Griffin SJ, Wagner EH, Van Eijk JT, Assendelft WJ. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care. 2001;24:1821-1833.
14. Sidorov J, Gabbay R, Harris R, et al. Disease management for diabetes mellitus: impact on hemoglobin A1c. Am J Manag Care. 2000;6:1217-1226.
15. Miller DB. Use of a chronic care model to direct the care of persons with diabetes in the capital health region of British Columbia. Ann RCPSC. 2002;35:495-498.
16. Hazard Munro B. Selected Nonparametric Techniques: Statistical Methods for Health Care Research. 3rd ed. Philadelphia, PA: JB Lippincott, 1997: 99-121.
17. Montori VM, Dinneen SF, Gorman CA, et al. The impact of planned care and a diabetes electronic management system on community-based diabetes care: the Mayo Health System Diabetes Translation Project. Diabetes Care. 2002;25:1952-1957.
18. Trento M, Passera P, Tomalino M, et al. Group visits improve metabolic control in type 2 diabetes: a 2-year follow-up. Diabetes Care. 2001;24:995-1000.
19. Gagliardino JJ, Etchegoyen G (PEDNID-LA Research Group). A model educational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA). Diabetes Care. 2001;24:1001-1007.
20. Schiel R, Ulbrich S, Muller UA. Quality of diabetes care, diabetes knowledge and risk of severe hypoglycaemia one and four years after participation in a 5-day structured treatment and teaching programme for intensified insulin therapy. Diabetes Metab. 1998;24:509-514.
21. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286:1218-1227.
22. Leibson CL, Williamson DF, Melton LJ III, et al. Temporal trends in BMI among adults with diabetes. Diabetes Care. 2001;24:1584-1589.
23. Looker HC, Knowler WC, Hanson RL. Changes in BMI and weight before and after the development of type 2 diabetes. Diabetes Care. 2001;24:1917-1922.
24. Tuomilehto J, Lindstrom J, Eriksson JG, et al (Finnish Diabetes Prevention Study Group). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
25. Sorensen TI. The changing lifestyle in the world: body weight and what else? Diabetes Care. 2000;23(Suppl 2): B1-B4.
26. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-797.
27. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
28. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-117.
29. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21-B29.
30. Klein R, Klein BE. Relation of glycemic control to diabetic complications and health outcomes. Diabetes Care. 1998;21(Suppl 3):C39-C43.
31. Hoey H, Aanstoot HJ, Chiarelli F, et al. Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes. Diabetes Care. 2001;24: 1923-1928.
32. Skinner TC, Hampson SE. Personal models of diabetes in relation to self-care, well-being, and glycemic control: a prospective study in adolescence. Diabetes Care. 2001;24:828-833.
33. Osende JI, Badimon JJ, Fuster V, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001;38:1307-1312.
34. Morioka T, Emoto M, Tabata T, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001;24:909-913.
35. Tuomilehto J. Interrupting the atherosclerotic process in diabetes: when and how should we treat? Adv Stud Med. 2002;2:800-807.
36. Greathouse M. New standards for lowering cholesterol in diabetic, female, and elderly patients: a clinician's point of view. Adv Stud Med. 2002;2:641-646.
37. Materson BJ, Preston RA. Prevention of diabetic nephropathy. Hosp Pract (Off Ed). 1997;32:129-134, 139-140.
38. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
39. Parving HH. Angiotensin II receptor blockade in the prevention of diabetic nephropathy. Am J Clin Pract. 2002;3:21-26.
40. Brenner BM, Cooper ME, de Zeeuw D, et al (RENAAL Study Investigators). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
41. Sasso FC, Carbonara O, Persico M, et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care. 2002;25:1909-1913.
42. Weir MR. Microalbuminuria as a cardiovascular and renal risk factor in patients with type 2 diabetes. Am J Clin Pract. 2002;3:7-14.
43. Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med. 2001;135:1079-1083.
44. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157-160.
45. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-172.
46. Leinung MC, Gianoukakis AG, Lee DW, Jeronis SL, Desemone J. Comparison of diabetes care provided by an endocrinology clinic and primary-care clinic. Endocr Pract. 2000;6:361-366.
47. Miller CD, Phillips LS, Tate MK, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care. 2000;23:444-448.